Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference
2024年6月5日 - 5:05AM
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical
company focused on the development and commercialization of novel
therapies for serious rare and ultrarare genetic diseases, today
announced that Emil Kakkis, M.D., Ph.D., the company's chief
executive officer, will participate in a fireside at the Goldman
Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11,
2024, at 10:00 a.m. ET.
The live and archived webcast of the panel will be accessible
from the company’s website at
https://ir.ultragenyx.com/events-presentations.
About Ultragenyx Pharmaceutical Inc.Ultragenyx
is a biopharmaceutical company committed to bringing novel products
to patients for the treatment of serious rare and ultrarare genetic
diseases. The company has built a diverse portfolio of approved
therapies and product candidates aimed at addressing diseases with
high unmet medical need and clear biology for treatment, for which
there are typically no approved therapies treating the underlying
disease.
The company is led by a management team experienced in the
development and commercialization of rare disease therapeutics.
Ultragenyx’s strategy is predicated upon time- and cost-efficient
drug development, with the goal of delivering safe and effective
therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's
website at: www.ultragenyx.com.
Contacts – Ultragenyx Pharmaceutical, Inc.InvestorsJoshua Higa
ir@ultragenyx.com
MediaCarolyn Wangmedia@ultragenyx.com
Ultragenyx Pharmaceutical (NASDAQ:RARE)
過去 株価チャート
から 8 2024 まで 9 2024
Ultragenyx Pharmaceutical (NASDAQ:RARE)
過去 株価チャート
から 9 2023 まで 9 2024